Arcutis Biotherapeutics
ARQT
ARQT
187 hedge funds and large institutions have $1.2B invested in Arcutis Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 73 increasing their positions, 48 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
187
Holders Change
+2
Holders Change %
+1.08%
% of All Funds
2.71%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
33
Increased
73
Reduced
48
Closed
31
Calls
$5.83M
Puts
$989K
Net Calls
+$4.84M
Net Calls Change
+$542K
Top Buyers
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
$102M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
$64.8M |
| 3 |
SC
Stempoint Capital
New York
|
$16.5M |
| 4 |
Goldman Sachs
New York
|
$14.8M |
| 5 |
D.E. Shaw & Co
New York
|
$16.2M |
